285
Views
28
CrossRef citations to date
0
Altmetric
Original Article

Retinal Vessel Caliber and Myopic Retinopathy: The Blue Mountains Eye Study

, , , , &
Pages 275-280 | Received 13 Mar 2011, Accepted 23 Jun 2011, Published online: 04 Nov 2011
 

Abstract

Purpose: To evaluate changes in the retinal vasculature in eyes with myopic retinopathy.

Methods: Population-based, cross-sectional study. Emmetropic and myopic participants from the Blue Mountains Eye Study baseline survey were included in this study. Myopia was defined as a refractive error of less than −1.00 diopter. Myopic retinopathy was defined if either staphyloma, lacquer crack, Fuchs’ spot or chorioretinal atrophy were present in myopic eyes. Retinal vascular caliber was measured from fundus photographs using standardized methods. The association of retinal vascular caliber with myopic retinopathy was assessed using generalized estimating equation models.

Results: A total of 2598 eyes of 1409 subjects were selected from 3654 baseline participants, with 2076 emmetropic eyes (normal controls), 486 myopic eyes without myopic retinopathy (myopic controls) and 36 myopic eyes with myopic retinopathy (cases). After adjusting for age, gender, height, body mass index and blood pressure, eyes with myopic retinopathy had significantly narrower mean arteriolar (166.6μm) and venular caliber (213.3μm), compared to normal (188.1μm and 226.9μm, respectively) or myopic control eyes (190.4μm and 227.0μm, respectively) (all P < 0.001). These retinal vessel caliber differences between myopic retinopathy and the two control groups remained significant after additional adjustment for refraction (all P < 0.001).

Conclusions: Our findings suggest that myopic retinopathy is associated with attenuation of retinal vessels.

ACKNOWLEDGMENTS

Source of Funding: Australian National Health & Medical Research Council (NHMRC, Project grant IDs: 153948, 211069 & 302068), Singapore Bioimaging Consortium (SBIC RP C-011/2006) and Biomedical Research Council (Grant No 501/1/25-5), and Pfizer Australia (Cardiovascular Lipid Grant 2007). JJW is funded by a National Health & Medical Research Council Senior Research Fellowship (2005–2014).

Declaration of interest: The authors report no conflict of interest. The authors alone are responsible for the content and writing of the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.